COVID-19 vaccine, protein subunit, Sepivac SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1
SARS-CoV-2, Vaccine, standardization, global, ELISA, Neutralization assays, ELISpot assays, protection from disease